Health ❯ Autoimmune Diseases
Dendritic Cell Diversity IPEX Syndrome Regulatory Mechanisms Disease Progression
The program narrows to non‑relapsing secondary progressive MS, with the U.S. decision now expected by the end of the first quarter of 2026.
